Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil - Piekos, Jacqueline A.; Amorim, Gustavo; Ridolfi, Felipe; Cordeiro-Santos, Marcelo; Kritski, Afrânio L.; Figueiredo, Marina C.; Andrade, Bruno B.; Santos, Adalberto R.; Haas, David W.; Sterling, Timothy R.; Rolla, Valeria C.; Edwards, Digna R. Velez; et al. (medRxiv, 2024)
Tuberculosis (TB) treatment is highly effective, but response to therapy can vary by geography, race, and ethnicity. We assessed for differences in TB treatment response in a representative and heterogeneous Brazilian population. We estimated genetic ancestry proportion according to major ancestry groups (African, European, and Amerindian ancestry) in the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil cohort. RePORT-Brazil is an observational prospective cohort study of individuals with newly-diagnosed, culture-confirmed, pulmonary TB. TB treatment outcomes that were attributed to TB treatment included Grade 2 or higher adverse drug reaction (ADR), Grade 3 or higher ADR, hepatic ADR, and failure/recurrence. Ancestry proportion was the main predictor in logistic regression for each outcome, with adjustments for candidate confounders. There were 941 pulmonary TB patients included in this study. We observed a decreased risk of Grade 2+ ADR when African ancestry proportion increased by 10% (Odds Ratio [OR] 0.41, 95% Confidence Interval [CI] 0.20 -0.85) and an increased risk for Grade 2+ ADR with increasing European ancestry (OR 2.84, 95% CI 1.47 - 5.48). We then performed the same analysis adding HIV status as an interaction term. The decreased risk for Grade 2+ ADR seen for African ancestry proportion did not hold for persons living with HIV; we observed increased risk for Grade 2+ ADR with increasing African ancestry proportion. There were no associations with Amerindian ancestry or for other treatment outcomes. In this Brazilian TB cohort, toxicity risk was associated with African and European ancestry, divergent, and affected by HIV.#RePORT-Brazil Consortium members include: Aline Benjamin and Flavia M. Sant’Anna Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, BrazilJamile Garcia de Oliveira and João Marine Clínica de Saúde Rinaldo Delmare, Rio de Janeiro, BrazilAdriana Rezende and Anna Cristina Carvalho Secretaria de Saúde de Duque de Caxias, Rio de Janeiro, BrazilMichael Rocha and Betânia Nogueira Instituto Brasileiro para Investigação da Tuberculose, Fundação José Silveira, Salvador, BrazilAlexandra Brito and Renata Spener Fundação Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, BrazilMegan Turner Vanderbilt University Medical Center, Nashville, USACompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Departamento de Ciencia e Tecnologia (DECIT), Secretaria de Ciencia e Tecnologia, Ministerio da Saude, Brazil (award number 25029.000507/2013-07 to V. C. R.); the National Institute of Allergy and Infectious Diseases, NIH (grant numbers U01 AI069923; U01 AI172064; R01 A1120790). L. K., M. C.-S., B. B. A., and V. C. R. are senior investigators and fellows from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil. The National Institute of Allergy and Infectious Diseases, NIH grants support also included AI077505 (to D. W. H.), AI110527, and TR000445.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The RePORT-Brazil study was approved by the institutional review board of the Instituto Nacional de Infectologia Evandro Chagas (CAAE: 25102412.3.1001.5262), by the institutional review boards of the other study sites, and Vanderbilt University Medical Center. Written informed consent was obtained from all participants and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors